Status:
COMPLETED
ESBA1008 Microvolume Study
Lead Sponsor:
Alcon Research
Conditions:
Exudative Age-Related Macular Degeneration
Eligibility:
All Genders
50+ years
Phase:
PHASE2
Brief Summary
The purpose of this study is to demonstrate a treatment effect of ESBA1008 applied as a microvolume injection or infusion on retinal function and morphology in subjects with exudative age-related macu...
Detailed Description
This 4-cohort study was conducted in 2 stages. Stage 1 consisted out of 2 Cohorts. In each cohort subjects were randomized 10:3 to either receive ESBA1008 (Cohort 1 : 2 injections, Cohort 2 : 1 infusi...
Eligibility Criteria
Inclusion
- Sign informed consent document;
- Able to make the required study visits and follow instructions;
- Age-related macular degeneration in the study eye;
- Visual acuity within protocol-specified range;
- 340 μm minimal central subfield thickness (CSFT; Spectralis Equivalent)
- Other protocol-defined inclusion criteria may apply.
Exclusion
- Both eyes: Any active infection or inflammation;
- Study eye: Any treatment for exudative age-related macular degeneration (AMD) other than vitamin supplements;
- Study eye: Any current or history of macular or retinal disease;
- Study eye: Any concurrent intraocular condition such as cataract or diabetic retinopathy that, in the opinion of the Investigator, could either require medical or surgical intervention during the course of the study to prevent or treat visual loss;
- Study eye: Other ocular conditions or diseases that, in the opinion of the Investigator, could compromise visual acuity;
- Study Eye: Uncontrolled glaucoma;
- History of a medical condition that, in the opinion of the Investigator, would preclude scheduled study visits, completion of the study, or a safe administration of investigational product;
- Women of childbearing potential who are lactating, pregnant, planning to become pregnant, or not using adequate birth control methods for the duration of the study;
- Intraocular surgery within 3 months of baseline;
- Study eye: Any history or current evidence of retinal angiomatous proliferation (RAP) lesions based on clinical exam;
- Other protocol-defined exclusion criteria may apply.
Key Trial Info
Start Date :
June 1 2013
Trial Type :
INTERVENTIONAL
Allocation :
ACTUAL
End Date :
January 1 2015
Estimated Enrollment :
107 Patients enrolled
Trial Details
Trial ID
NCT01849692
Start Date
June 1 2013
End Date
January 1 2015
Last Update
March 24 2016
Active Locations (0)
Enter a location and click search to find clinical trials sorted by distance.
No Results Found
We couldn’t find results for the location/zipcode entered or within the selected range. Please check your input or adjust your search.